|
| Wednesday, January 19, 2022 |
|
|
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study |
| Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). more info >> |
|
| Monday, January 17, 2022 |
|
|
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022. more info >> |
|
| Thursday, January 13, 2022 |
|
|
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health) |
| Eisai Co., Ltd. announced today that its Taiwanese subsidiary Eisai Taiwan Inc. and Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. have launched "CogMateTM", a digital tool (non-medical device) for self-assessment of brain performance (brain health). more info >> |
|
| Thursday, January 6, 2022 |
|
|
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator |
| Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. more info >> |
|
| Friday, December 24, 2021 |
|
|
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation |
| Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early Alzheimer's disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
| Tuesday, December 21, 2021 |
|
|
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States |
| Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200. more info >> |
|
| Monday, December 20, 2021 |
|
|
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia |
| Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib. more info >> |
|
| Monday, December 6, 2021 |
|
|
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eribulin mesylate (product name: Halaven, halichondrin class microtubule dynamics inhibitor, "eribulin"), MORAb-202, an antibody drug conjugate (ADC), and H3B-6545 (selective estrogen alpha receptor covalent antagonist). more info >> |
|
| Tuesday, November 30, 2021 |
|
|
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
| Eisai Co., Ltd. and FCNT LIMITED announced today that both companies have entered into a business alliance agreement aiming to support people living with dementia and to prevent dementia, through developing solutions for maintaining brain performance. more info >> |
|
|
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced today that the company will conduct a total of 42 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) and in-house discovered and developed E2730 at the 75th American Epilepsy Society Annual Meeting (AES2021), to be held in Chicago, Illinois and virtually from December 3 to 7, 2021. more info >> |
|
|
|
